36 krypton learned that Jianjia robot, an R & D and production enterprise of intelligent orthopedic surgical robot, has completed a round of financing of tens of millions of yuan at the beginning of this year. The investor is bv Baidu venture capital, and Haoyue capital acts as the exclusive financial adviser for this round of financing. This round of financing will be used to promote the clinical trial of the company's first joint replacement robot "artrobot".
Jianjia robot was established in 2018, focusing on providing accurate joint replacement scheme for the market, covering the whole process of "preoperative, intraoperative and postoperative":
? preoperative - the intelligent preoperative planning software can process data at the terminal, design the operation scheme interactively with doctors, and shorten the preoperative preparation time through calibration automation and registration algorithm;
? intraoperative - through accurate robot operation control, gravity compensation and multi-mode switching functions, help doctors carry out accurate operation, simplify surgical steps and provide better hand feeling;
? postoperative - relying on the real-time postoperative evaluation system to help doctors quickly and stereoscopically understand the implementation effect of surgery.
In a word, the key Jia robot is intended to improve the accuracy and stability of the surgical operation of joint surgeons, and protect doctors and patients from intraoperative radiation exposure, so as to reduce the incidence of postoperative complications and greatly shorten the learning curve of doctors.
Xu Jing, founder of Jianjia robot, said that in recent years, the international orthopaedic instrument giants have made great efforts to layout the field of orthopaedic surgical robots, and the future trend has emerged. Jianjia robot can solve the clinical pain points with poor effect of joint replacement surgery and few clinician resources, and then boost the outbreak of the whole joint surgery market and orthopedic market in China.
Xu Jing also said that in the future, Jianjia will accelerate the clinical trial and R & D process of orthopaedic surgical robot and strive to become an intelligent surgical housekeeper for orthopaedic doctors as soon as possible. The vision is put into the whole market. At present, the device giant Stryker with orthopedic implants as the core has a market value of about 380 billion yuan, and its Mako joint surgery robot system has been widely used all over the world. The data show that only in the United States, Mako joint surgery robot system, the total number of operations in 2019 exceeded 114000, and the operation penetration rate was close to 10%.
In contrast, in China, the number of artificial joint replacement surgeries exceeded 700000 in 2019, and maintained a rapid growth of more than 20% year after year. However, the satisfaction rate of domestic patients with joint surgery is not high, and they rely very much on doctors' experience and surgical skills.
Correspondingly, at present, no domestic orthopaedic joint replacement surgery robot has been registered and approved. In the face of such a huge blank market, Jianjia's first joint replacement surgery robot product "artrobot" has entered the clinical trial stage and is expected to become the first domestic joint replacement surgery robot to obtain nmpa registration certificate, with fast guns accounting for the market.
In terms of team, Jianjia robot project was born out of the National 863 plan. The core technical team comes from the National Laboratory of intelligence and systems of Tsinghua University, and senior orthopedic clinical experts participate in front-line R & D.
